David Raben

22.8k total citations · 6 hit papers
236 papers, 15.2k citations indexed

About

David Raben is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology. According to data from OpenAlex, David Raben has authored 236 papers receiving a total of 15.2k indexed citations (citations by other indexed papers that have themselves been cited), including 114 papers in Oncology, 111 papers in Pulmonary and Respiratory Medicine and 77 papers in Otorhinolaryngology. Recurrent topics in David Raben's work include Head and Neck Cancer Studies (76 papers), Lung Cancer Treatments and Mutations (58 papers) and Advanced Radiotherapy Techniques (30 papers). David Raben is often cited by papers focused on Head and Neck Cancer Studies (76 papers), Lung Cancer Treatments and Mutations (58 papers) and Advanced Radiotherapy Techniques (30 papers). David Raben collaborates with scholars based in United States, Canada and Spain. David Raben's co-authors include Robert L. Ferris, Athanassios Argiris, Michalis V. Karamouzis, Paul M. Harari, J. Giralt, James A. Bonner, José Baselga, Christopher U. Jones, Roger B. Cohen and Ranjan Sur and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

David Raben

230 papers receiving 14.9k citations

Hit Papers

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma o... 2006 2026 2012 2019 2006 2008 2009 2011 2014 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
    2006 3.7k citations James A. Bonner, Paul M. Harari et al. profile →
  2. Head and neck cancer
    2008 1.8k citations Athanassios Argiris, Michalis V. Karamouzis et al. The Lancet profile →
  3. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
    2009 1.4k citations James A. Bonner, Paul M. Harari et al. The Lancet Oncology profile →
  4. Caspase 3–mediated stimulation of tumor cell repopulation during cancer radiotherapy
    2011 706 citations Aik Choon Tan, Gangwen Han et al. profile →
  5. p16 Protein Expression and Human Papillomavirus Status As Prognostic Biomarkers of Nonoropharyngeal Head and Neck Squamous Cell Carcinoma
    2014 289 citations Paul M. Harari, David Raben et al. Journal of Clinical Oncology profile →
  6. Deciphering T-cell exhaustion in the tumor microenvironment: paving the way for innovative solid tumor therapies
    2025 21 citations David Raben et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Raben United States 48 6.8k 5.6k 5.2k 4.4k 3.7k 236 15.2k
Paul M. Harari United States 60 8.6k 1.3× 7.2k 1.3× 5.9k 1.1× 4.7k 1.1× 4.0k 1.1× 303 18.1k
James A. Bonner United States 53 6.6k 1.0× 6.6k 1.2× 4.8k 0.9× 3.0k 0.7× 3.1k 0.9× 232 14.0k
Ezra E.W. Cohen United States 67 8.5k 1.2× 5.6k 1.0× 4.7k 0.9× 4.7k 1.1× 3.2k 0.9× 421 16.9k
Christine H. Chung United States 52 5.6k 0.8× 3.6k 0.6× 7.2k 1.4× 4.7k 1.1× 4.5k 1.2× 255 15.6k
Bonnie S. Glisson United States 61 7.7k 1.1× 4.6k 0.8× 5.9k 1.1× 4.0k 0.9× 5.0k 1.4× 275 14.8k
Dora L.�W. Kwong Hong Kong 53 3.4k 0.5× 3.0k 0.5× 4.1k 0.8× 3.3k 0.7× 3.5k 1.0× 219 11.1k
J. Giralt Spain 29 5.3k 0.8× 4.6k 0.8× 5.7k 1.1× 2.2k 0.5× 4.3k 1.2× 118 11.7k
Merrill S. Kies United States 57 7.3k 1.1× 5.3k 1.0× 5.7k 1.1× 2.7k 0.6× 5.2k 1.4× 178 14.6k
Barbara Burtness United States 56 8.5k 1.3× 5.0k 0.9× 5.0k 1.0× 4.4k 1.0× 3.7k 1.0× 363 16.0k
K. Kian Ang United States 54 4.2k 0.6× 4.5k 0.8× 5.3k 1.0× 1.8k 0.4× 3.9k 1.1× 177 11.6k

Countries citing papers authored by David Raben

Since Specialization
Citations

This map shows the geographic impact of David Raben's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Raben with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Raben more than expected).

Fields of papers citing papers by David Raben

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Raben. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Raben. The network helps show where David Raben may publish in the future.

Co-authorship network of co-authors of David Raben

This figure shows the co-authorship network connecting the top 25 collaborators of David Raben. A scholar is included among the top collaborators of David Raben based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Raben. David Raben is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Keysar, Stephen B., Nathan Gomes, Bettina Miller, et al.. (2020). Inhibiting Translation Elongation with SVC112 Suppresses Cancer Stem Cells and Inhibits Growth in Head and Neck Squamous Carcinoma. Cancer Research. 80(5). 1183–1198. 16 indexed citations
2.
Young, Christian D., Li Bian, Kelsey Weigel, et al.. (2020). PARP Inhibition Enhances Radiotherapy of SMAD4-Deficient Human Head and Neck Squamous Cell Carcinomas in Experimental Models. Clinical Cancer Research. 26(12). 3058–3070. 25 indexed citations
3.
Bhatia, Shilpa, Ayman Oweida, Shelby Lennon, et al.. (2019). Inhibition of EphB4–Ephrin-B2 Signaling Reprograms the Tumor Immune Microenvironment in Head and Neck Cancers. Cancer Research. 79(10). 2722–2735. 38 indexed citations
4.
Karam, Sana D. & David Raben. (2019). Radioimmunotherapy for the treatment of head and neck cancer. The Lancet Oncology. 20(8). e404–e416. 68 indexed citations
5.
Bhatia, Shilpa, Shelby Lennon, Ayman Oweida, et al.. (2018). Role of EphB3 Receptor in Mediating Head and Neck Tumor Growth, Cell Migration, and Response to PI3K Inhibitor. Molecular Cancer Therapeutics. 17(9). 2049–2059. 9 indexed citations
6.
Luo, Jingjing, Li Bian, Melanie A. Blevins, et al.. (2018). Smad7 Promotes Healing of Radiotherapy-Induced Oral Mucositis without Compromising Oral Cancer Therapy in a Xenograft Mouse Model. Clinical Cancer Research. 25(2). 808–818. 27 indexed citations
7.
Karam, Sana D., Krishna Reddy, Patrick J. Blatchford, et al.. (2018). Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer. Clinical Cancer Research. 24(20). 4949–4959. 68 indexed citations
8.
Bhatia, Shilpa, Jaspreet Sharma, Sanjana Bukkapatnam, et al.. (2018). Inhibition of EphB4–Ephrin-B2 Signaling Enhances Response to Cetuximab–Radiation Therapy in Head and Neck Cancers. Clinical Cancer Research. 24(18). 4539–4550. 23 indexed citations
9.
Oweida, Ayman, Mohammad K. Hararah, Andy V. Phan, et al.. (2018). Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration. Clinical Cancer Research. 24(21). 5368–5380. 209 indexed citations
10.
Cicchini, Louis, Rachel Z. Blumhagen, Joseph A. Westrich, et al.. (2017). High-Risk Human Papillomavirus E7 Alters Host DNA Methylome and Represses HLA-E Expression in Human Keratinocytes. Scientific Reports. 7(1). 3633–3633. 44 indexed citations
11.
12.
Galloway, Thomas J., Lori J. Wirth, A. D. Colevas, et al.. (2015). A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research. 21(7). 1566–1573. 84 indexed citations
13.
Gan, Gregory N., Justin R. Eagles, Stephen B. Keysar, et al.. (2014). Hedgehog Signaling Drives Radioresistance and Stroma-Driven Tumor Repopulation in Head and Neck Squamous Cancers. Cancer Research. 74(23). 7024–7036. 59 indexed citations
14.
Kavanagh, Brian D., Tracey E. Schefter, René González, et al.. (2010). Stereotactic Body Radiation Therapy for Melanoma and Renal Cell Carcinoma: Impact of Single Fraction Equivalent Dose on Local Control. International Journal of Radiation Oncology*Biology*Physics. 78(3). S190–S191. 10 indexed citations
15.
Sclafani, Robert A., Sunitha Siriwardana, Barbara Frederick, et al.. (2009). Abstract #3989: Combined Resveratrol and radiation therapy in head and neck cancer. Cancer Research. 69. 3989–3989. 2 indexed citations
16.
Bradshaw‐Pierce, Erica L., et al.. (2008). Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma. Molecular Cancer Therapeutics. 7(9). 3006–3017. 14 indexed citations
17.
Argiris, Athanassios, Michalis V. Karamouzis, David Raben, & Robert L. Ferris. (2008). Head and neck cancer. The Lancet. 371(9625). 1695–1709. 1827 indexed citations breakdown →
18.
Rosenfeld, M E, M B Khazaeli, Galina Mikheeva, et al.. (1997). Adenoviral-mediated delivery of gastrin-releasing peptide receptor results in specific tumor localization of a bombesin analogue in vivo.. PubMed. 3(7). 1187–94. 9 indexed citations
19.
Smith, Barbara L., Ruben Baumgarten, Søren Nielsen, et al.. (1993). Concurrent expression of erythroid and renal aquaporin CHIP and appearance of water channel activity in perinatal rats.. Journal of Clinical Investigation. 92(4). 2035–2041. 61 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paul M. Harari Breakdown of academic impact, for papers by James A. Bonner Breakdown of academic impact, for papers by Ezra E.W. Cohen Breakdown of academic impact, for papers by Christine H. Chung Breakdown of academic impact, for papers by Bonnie S. Glisson Breakdown of academic impact, for papers by Dora L.�W. Kwong Breakdown of academic impact, for papers by J. Giralt Breakdown of academic impact, for papers by Merrill S. Kies Breakdown of academic impact, for papers by Barbara Burtness Breakdown of academic impact, for papers by K. Kian Ang
Rankless by CCL
2026